Long Focus Capital Management LLC Increases Stock Holdings in Insmed Incorporated (NASDAQ:INSM)

Long Focus Capital Management LLC boosted its holdings in Insmed Incorporated (NASDAQ:INSM - Free Report) by 3.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 650,800 shares of the biopharmaceutical company's stock after purchasing an additional 21,900 shares during the period. Insmed makes up 1.5% of Long Focus Capital Management LLC's portfolio, making the stock its 13th largest position. Long Focus Capital Management LLC owned 0.36% of Insmed worth $44,931,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. Norges Bank purchased a new stake in Insmed during the 4th quarter valued at about $126,606,000. Vanguard Group Inc. lifted its position in Insmed by 6.3% in the fourth quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company's stock valued at $1,257,838,000 after purchasing an additional 1,075,796 shares during the last quarter. Capital International Investors boosted its stake in shares of Insmed by 9.1% during the fourth quarter. Capital International Investors now owns 7,116,997 shares of the biopharmaceutical company's stock valued at $491,357,000 after purchasing an additional 593,206 shares during the period. B Group Inc. bought a new position in shares of Insmed in the fourth quarter worth approximately $24,164,000. Finally, Marshall Wace LLP increased its stake in shares of Insmed by 38.0% in the fourth quarter. Marshall Wace LLP now owns 1,064,215 shares of the biopharmaceutical company's stock worth $73,473,000 after buying an additional 293,004 shares during the period.

Analyst Ratings Changes

INSM has been the subject of several analyst reports. Bank of America increased their price target on shares of Insmed from $92.00 to $96.00 and gave the company a "buy" rating in a research report on Thursday, March 20th. Morgan Stanley raised their price target on Insmed from $85.00 to $90.00 and gave the stock an "overweight" rating in a research note on Thursday, February 6th. UBS Group boosted their price objective on shares of Insmed from $105.00 to $110.00 and gave the company a "buy" rating in a research report on Thursday, March 6th. JPMorgan Chase & Co. raised their target price on shares of Insmed from $83.00 to $92.00 and gave the stock an "overweight" rating in a research report on Friday, February 7th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $90.00 price target on shares of Insmed in a research note on Tuesday, April 22nd. One investment analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $94.00.

Insmed Stock Performance

Shares of INSM stock traded down $0.05 during trading hours on Monday, reaching $69.64. The company had a trading volume of 1,506,498 shares, compared to its average volume of 2,303,594. The firm has a market cap of $12.66 billion, a PE ratio of -12.46 and a beta of 1.07. Insmed Incorporated has a one year low of $21.92 and a one year high of $84.91. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The business has a fifty day moving average price of $74.38 and a 200-day moving average price of $73.57.

Insmed (NASDAQ:INSM - Get Free Report) last announced its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.15). The business had revenue of $104.44 million for the quarter, compared to the consensus estimate of $102.31 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. Sell-side analysts predict that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Orlov S. Nicole Schaeffer sold 91,140 shares of the firm's stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $80.00, for a total transaction of $7,291,200.00. Following the completion of the transaction, the insider now owns 97,083 shares in the company, valued at $7,766,640. This trade represents a 48.42 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO William Lewis sold 6,830 shares of Insmed stock in a transaction that occurred on Tuesday, April 15th. The stock was sold at an average price of $70.16, for a total value of $479,192.80. Following the completion of the sale, the chief executive officer now directly owns 233,924 shares in the company, valued at approximately $16,412,107.84. The trade was a 2.84 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 471,797 shares of company stock valued at $37,621,239. 3.00% of the stock is owned by corporate insiders.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.